ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has sold 32,142,858 additional shares of its common stock to the public for $225 million, before deducting underwriting discounts, commissions, and other offering expenses.
In addition, Esperion granted the underwriter a 30-day option to purchase up to an additional 4,821,428 shares of its common stock or additional warrants to purchase up to 4,821,428 shares of its common stock, which the underwriter has partially exercised for warrants to purchase 4,821,428 shares of common stock.
At closing, Esperion received net proceeds from the offering of approximately $208.8 million. All of the securities sold in the offering were offered by Esperion.
Esperion intends to use the net proceeds from the offering to fund the ongoing commercialization efforts for its cholesterol-reducing drugs Nexletol and Nexlizet, research and clinical development of current or additional pipeline candidates, and general corporate purposes.
H.C. Wainwright & Co. acted as sole book-running manager for the public offering.
The final prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the offering may also be obtained by contacting H.C. Wainwright & Co., LLC, at 430 Park Ave., New York, New York 10022, by telephone at (212) 856-5711, or by email at email@example.com.
More at www.esperion.com.